Clinical Trial Update: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL [Phase 3]

View source ↗

Summary

Phase 3 study evaluating acalabrutinib (ACP-196) with venetoclax, with and without obinutuzumab (GA101), versus chemoimmunotherapy in previously untreated chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING